Clinical - Phase News: Breaking Clinical - Phase News, Comments and Articles. - Page: 4

Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

French drug major Sanofi (Euronext: SAN) and US biotech partner Regeneron Pharmaceuticals (Nasdaq: REGN) announced that the New England Journal of Medicine published on-line the positive Phase IIa study results of dupilumab (SAR231893REGN668) in pati...

Phagenesis Expands Series B Financing to $17 million

Manchester, UK – 22 May 2013 − Phagenesis, the world’s leading company in the treatment of dysphagia, has expanded its Series B financing to $17m. In 2011, Phagenesis announced a €7m Series B financing, led by Inventages Venture Capital. The increased resources will be used to launch the Phagenyx® treatment, which received its CE Mark in 2012, in new territories an...

Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer

BUFFALO, N.Y., May 22, 2013 /PRNewswire/ -- Empire Genomics announced today it has acquired an exclusive license for a patent pending novel genomic biomarker from Cornell University for use in developing a molecular diagnostic test that could help in diagnosing and determining treatment for patients with neuroendocrine (NEPC) prostate cancer.  Neuroendocrine prostate cancer (NEPC) is a...

Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency

PHILADELPHIA, May 22, 2013 /PRNewswire/ -- Grifols, a global healthcare company based in Barcelona, Spain, presented results from a study demonstrating that a higher dose of PROLASTIN©-C (Alpha1-Proteinase Inhibitor [Human]) increased levels of the alpha1 protein in patients with alpha1antitrypsin (AAT) deficiency to levels that are considered within the normal range for healthy individu...

Accenture Helps NHS Radiologists Exchange Medical Images in the Cloud

New system enables clinicians to access images in real-time across hospitals/medical facilities in Southwest England Accenture (NYSE:ACN) has completed the deployment of a cloud-based Radiology Information System (RIS) for five hospitals and 23 facilities within the National Health Service (NHS) in Southwest England. Using

AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA

Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday (May 21) presented the results of two pivotal Phase III studies of naloxegol showing the 25mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a...

Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors

NEW YORK, May 22, 2013 /PRNewswire/ -- Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs, today announced the appointment of June S. Almenoff, M.D., Ph.D., to its Board of Directors. Dr. Almenoff has extensive experience in the pharmaceutical industry, working on early and late stage drug development. "We...

The 'New' Celsion Could Be Worth $4 A Share

ByQuoth the Raven: Four Bagger? Am I Nuts? No, I am not. Here's why a four-bagger is definitely possible. Celsion (CLSN) traded at $8 before the Phase III results were announced. After diluting by 50%, if it were to trade the same market cap on the hopes of ThermoDox possibly being approved again, we'd easily be back over $3 heading to $4. If the data continues to come out in favor of ThermoDox,...

Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference

COLUMBIA, Md. and TORONTO, May 22, 2013 /PRNewswire/ -- Medifocus, Inc. (OTCQX: MDFZF and TSXV: MFS)  announced today that John Mon, Chief Operating Officer, will present at the Second Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in New York City at the Grand Hyatt Hotel. The Company's presentation is scheduled to begin at 4:00 p.m. EDT and will be available via a li...

Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology

SAN DIEGO, May 22, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) today announced that data from clinical investigations of quizartinib (AC220), a potent and selective FLT3 inhibitor, will be presented at the Annual Meeting of the American Society of Clinical Oncology, held May 31 through June 4, 2013, at McCormick Place in Chicago. Information about the abstracts, including p...

Can-Fite BioPharma To Present At The Second Annual Marcum LLP MicroCap Conference

PETACH TIKVA, Israel, May 22, 2013 /PRNewswire/ -- Can-Fite BioPharma (TASE: CFBI, OTC: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that Pnina Fishman, Chief Executive Officer of Can-Fite BioPharma will present at the Second Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in New Y...

Celsion Announces Issuance of Additional Patents Covering ThermoDox® Technologies

LAWRENCEVILLE, N.J., May 22, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that its proprietary patent application, "Method of Storing Nanoparticle Formulations," has now been granted in the four largest markets for liver cancer globally:  China, Japan, South Korea and most recently Taiwan.  Celsion holds an exclusive license agreement with Duke University...

Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer

PALO ALTO, Calif., May 22, 2013 /PRNewswire/ -- Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has achieved half of the enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer. To da...

CareFusion Foundation Announces Clinical Excellence Grant Recipients

SAN DIEGO, May 22, 2013 /PRNewswire/ -- The CareFusion Foundation today announced the recipients of more than $500,000 in grant funding to help develop and share infection prevention best practices. Grants of up to $50,000 were awarded to 11 U.S. nonprofit health care institutions as part of the Foundation's inaugural Clinical Excellence Grant Program. "Infection prevention is a critical concern...

Succesful results in developing oral vaccine against diarrhea

The University of Gothenburg Vaccine Research Institute (GUVAX) announces successful results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.

NIH funds studies to improve type 2 and prediabetes treatment

The National Institutes of Health is looking for volunteers to take part in one of three clinical trials to improve and preserve the production of insulin in people with prediabetes or recently diagnosed type 2 diabetes. The project is called the Restoring Insulin Secretion study (RISE).

For Bifurcation Lesions in Coronary Arteries, Medtronic's Resolute Stent Delivers Strong Long-Term Results

Three Analyses Presented at EuroPCR Demonstrate Device's Durability in Addressing Common Clinical Challenge PARIS -- May 22, 2013 -- Addressing one of the most common clinical challenges in the treatment of complex coronary artery disease, three separate analyses on the program for EuroPCR this week show how strongly the Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) performs...

Oral vaccine against diarrhea promising

Medical researchers have announced promising results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.

China Pharmaceutical Market Guidebook Series (4) 2013 Report

DALLAS, May 22, 2013 /PRNewswire-iReach/ -- MarketReportsOnline.com announces addition of new market research report "China Pharmaceutical Guidebook Series (4) 2013 Edition Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Traditional Chinese Medicines and Natural Medicines" to its online databa...

Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye

SOUTH SAN FRANCISCO, Calif., May 22, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the clinical advancement of three programs in development. The first program is a wholly-owned topical ophthalmic formulation of a JAK/SYK inhibitor, R348, being developed by Rigel as a treatment for dry eye disease.  The other two programs are aimed at oncology targets and are...

Neuralstem Phase I Results Encourage Market, Stimulate Buying

By Brian L. Wilson:Although it seems that investors have lost their appetite for many stem cell investments at this stage of the broader rally in the stock market, there are exceptions worth pointing out. Neuralstem (NASDAQ: CUR), for instance, has been in a strong uptrend since, on April 17th, the company finally received approval from the FDA to commence a Phase II clinical trial in 18 patients...

Japan hospital tests powerful breast cancer therapy

A Japanese cancer specialist said Wednesday she has started the world's first clinical trial of a powerful, non-surgical, short-term radiation therapy for breast cancer.

Omeros to Present at Two Upcoming Conferences

SEATTLE, May 22, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the following two conferences: 38t...

Soligenix Announces Issuance of US Patent for its ThermoVax™ Technology

PRINCETON, N.J., May 22, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that the US Patent and Trademark Office granted patent 8,444,991 entitled "Method of Preparing a...

Naloxegol meets primary and secondary endpoints in two pivotal Phase III studies

AstraZeneca today presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies...